Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Gains from Sales and Divestitures (2019 - 2022)

Historic Gains from Sales and Divestitures for Cue Biopharma (CUE) over the last 4 years, with Q4 2022 value amounting to $98335.0.

  • Cue Biopharma's Gains from Sales and Divestitures fell 2531.54% to $98335.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $98335.0, marking a year-over-year decrease of 2531.54%. This contributed to the annual value of $98335.0 for FY2022, which is 2531.54% down from last year.
  • Latest data reveals that Cue Biopharma reported Gains from Sales and Divestitures of $98335.0 as of Q4 2022, which was down 2531.54% from $98335.0 recorded in Q3 2022.
  • Over the past 5 years, Cue Biopharma's Gains from Sales and Divestitures peaked at $131667.0 during Q4 2021, and registered a low of $16666.0 during Q1 2020.
  • In the last 4 years, Cue Biopharma's Gains from Sales and Divestitures had a median value of $56665.0 in 2020 and averaged $60769.2.
  • Examining YoY changes over the last 5 years, Cue Biopharma's Gains from Sales and Divestitures showed a top increase of 45003.0% in 2022 and a maximum decrease of 2531.54% in 2022.
  • Over the past 4 years, Cue Biopharma's Gains from Sales and Divestitures (Quarter) stood at $33333.0 in 2019, then soared by 70.0% to $56665.0 in 2020, then surged by 132.36% to $131667.0 in 2021, then decreased by 25.32% to $98335.0 in 2022.
  • Its Gains from Sales and Divestitures was $98335.0 in Q4 2022, compared to $98335.0 in Q3 2022 and $91668.0 in Q2 2022.